再生一个吧。
IPAH has no cure. Untreated IPAH leads to right-sided heart failure and
death. Prior to the 1990s, therapeutic options were limited. The emergence
of prostacyclin analogues, endothelin receptor antagonists,
phosphodiesterase-5 inhibitors, and other novel drug therapies has greatly
improved the outlook for patients with IPAH and IPAH-like diseases.
For untreated IPAH, the estimated 3-year survival rate is approximately 41%.
In one study of long-term continuous intravenous prostacyclin therapy, 3-
year survival increased to approximately 63%.[15] With newer therapies,
perhaps in combination, these figures are expected to improve further.